<DOC>
	<DOCNO>NCT00761319</DOCNO>
	<brief_summary>The purpose study compare two ophthalmic solution patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Phase III Clinical Trial TRAVATAN Z Ocular Surface Health</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>18 year old . Ocular Surface Disease Index ( OSDI ) score corneal fluorescein stain score specify protocol . Diagnosis openangle glaucoma ocular hypertension least one eye . Intraocular pressure ( IOP ) control latanoprost 0.005 % ( XALATANÂ® ) least one continuous month prior Visit 1 . Willing able discontinue use topical ocular medicine study medication duration study , include artificial tear . Best correct visual acuity 0.6 logMAR good eye . Other protocoldefined inclusion criterion may apply . Any medical condition ( systemic ophthalmic ) may preclude safe administration test article . Use contact lens within 30 day Visit 1 . Use contact lens study . Participation investigational drug device study within 30 day enter study . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
</DOC>